FDA warned Eden Health International that its telehealth website misbrands compounded semaglutide and tirzepatide with false or misleading claims.
What happened
FDA reviewed Eden’s website, https://www.tryeden.com, in March 2026 and found it offered compounded semaglutide and tirzepatide products. FDA said the pictured labels identify “Eden,” suggesting Eden is the compounder when it is not. FDA also said the site claims the products are sourced from “FDA-licensed 503(a) outsourcing facilities,” although FDA does not establish an FDA-approved or FDA-licensed designation for pharmacies or outsourcing facilities.
What FDA found
The website’s label images identify “Eden” on compounded semaglutide and tirzepatide products, suggesting Eden is the compounder when it is not.
FD&C Act § 502(a) [21 U.S.C. § 352(a)]; 21 C.F.R. § 201.1(h)(2)The website says the compounded products are sourced from “FDA-licensed 503(a) outsourcing facilities,” but FDA does not license or approve compounding pharmacies or outsourcing facilities.
FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The false or misleading representations make the compounded drug products misbranded and their introduction into interstate commerce a prohibited act.
FD&C Act §§ 301(a), 502(a), 502(bb) [21 U.S.C. §§ 331(a), 352(a), 352(bb)]
What FDA wants
FDA asks Eden to send a written response within 15 business days with the steps taken to correct the violations, an explanation of steps to prevent recurrence, copies of related documentation, identification of the entities producing the compounded products, sample labeling, and changes to or removal of the false or misleading website claims.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- online pharmacies and marketers of compounded drugs
- compounding pharmacies or outsourcing facilities named in third-party marketing
This is a summary. Read the original letter on fda.gov.